Laboratorios Farmaceuticos Rovi, S.A.

OTCPK:LABF.F Stock Report

Market Cap: US$3.6b

Laboratorios Farmaceuticos Rovi Past Earnings Performance

Past criteria checks 4/6

Laboratorios Farmaceuticos Rovi's earnings have been declining at an average annual rate of -1%, while the Pharmaceuticals industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 3.1% per year. Laboratorios Farmaceuticos Rovi's return on equity is 25.8%, and it has net margins of 24%.

Key information

-0.96%

Earnings growth rate

3.40%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate3.08%
Return on equity25.81%
Net Margin23.95%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Laboratorios Farmaceuticos Rovi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:LABF.F Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 267731851750
31 Mar 267411321630
31 Dec 257431401600
30 Sep 257241211650
30 Jun 257491321640
31 Mar 257671401610
31 Dec 247641371580
30 Sep 247991651550
30 Jun 247781481530
31 Mar 247791381500
31 Dec 238301701470
30 Sep 238371971430
30 Jun 238181861380
31 Mar 238141941340
31 Dec 228182001300
30 Sep 227611761150
30 Jun 227391831100
31 Mar 227241821080
31 Dec 216491531030
30 Sep 21581113950
30 Jun 2151982940
31 Mar 2145071860
31 Dec 2042061850
30 Sep 2041355930
30 Jun 2039553910
31 Mar 2040046930
31 Dec 1938139920
30 Sep 1935533930
30 Jun 1933427930
31 Mar 1931018910
31 Dec 1830318910
30 Sep 1829116900
30 Jun 182839880
31 Mar 1828418870
31 Dec 1727617850
30 Sep 1727722810
30 Jun 1727524810
31 Mar 1727223800
31 Dec 1626526800
30 Sep 1626025840
30 Jun 1625424840
31 Mar 1624623850
31 Dec 1524620840
30 Sep 152422153-9

Quality Earnings: LABF.F has a large one-off gain of €62.4M impacting its last 12 months of financial results to 30th June, 2026.

Growing Profit Margin: LABF.F's current net profit margins (24%) are higher than last year (17.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LABF.F's earnings have declined by 1% per year over the past 5 years.

Accelerating Growth: LABF.F's earnings growth over the past year (40%) exceeds its 5-year average (-1% per year).

Earnings vs Industry: LABF.F earnings growth over the past year (40%) exceeded the Pharmaceuticals industry 1%.

Return on Equity

High ROE: LABF.F's Return on Equity (25.8%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/22 10:44
End of Day Share Price 2026/08/03 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Laboratorios Farmaceuticos Rovi, S.A. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luis ArredondoBanco de Sabadell. S.A.
Jaime EscribanoBanco Santander
Patricia CifuentesBestinver Sociedad De Valores, S.A